In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

In this study suitability of α-ZrP nanoparticles as a 223 Ra and 225 Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of rel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of radioanalytical and nuclear chemistry 2023-05, Vol.332 (5), p.1527-1532
Hauptverfasser: Sakmár, Michal, Ondrák, Lukáš, Fialová, Kateřina, Vlk, Martin, Kozempel, Ján, Bruchertseifer, Frank, Morgenstern, Alfred
Format: Artikel
Sprache:eng
Schlagworte:
Chemistry
Chemistry and Materials Science
Diagnostic Radiology
Hadrons
Heavy Ions
Inorganic Chemistry
Nanoparticles
Nuclear Chemistry
Nuclear Physics
Physical Chemistry
Progeny
Radioisotopes
Radiolabelling
Stability
Zirconium
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this study suitability of α-ZrP nanoparticles as a 223 Ra and 225 Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of released radioactivity showed the highest stability in saline. Released activity of 223 Ra, 225 Ac and their daughter radionuclides was around 0.5%. On the other hand, the lowest stability was shown in plasma and serum. Released activity for 223 Ra, 225 Ac and their progeny atoms was from 15 to 32%.
ISSN:0236-5731
1588-2780
DOI:10.1007/s10967-022-08742-y